Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

VTYX

Ventyx Biosciences Inc

Dec 01 • 04:00PM ET

2.20

Dollar change +0.04
Percentage change 1.85	%

Healthcare • Biotechnology • USA • NASD

Stock Detail • Compare Perf. • Options Chain • Save to Portfolio • Create Alert

Scroll to Statements

Index	RUT	P/E	-	EPS (ttm)	-3.12	Insider Own	24.52%	Shs Outstand	56.98M	Perf Week	-9.84%
Market Cap	129.73M	Forward P/E	-	EPS next Y	-3.01	Insider Trans	-8.66%	Shs Float	44.51M	Perf Month	-84.76%
Income	-181.42M	PEG	-	EPS next Q	-0.86	Inst Own	86.58%	Short Float / Ratio	13.28% / 2.77	Perf Quarter	-93.48%
Sales	0.00M	P/S	-	EPS this Y	-62.32%	Inst Trans	8.93%	Short Interest	5.91M	Perf Half Y	-93.53%
Book/sh	4.81	P/B	0.46	EPS next Y	10.42%	ROA	-48.89%	Target Price	14.22	Perf Year	-92.41%
Cash/sh	5.10	P/C	0.43	EPS next 5Y	-	ROE	-54.39%	52W Range	2.13 - 47.25	Perf YTD	-93.29%
Dividend	-	P/FCF	-	EPS past 5Y	-	ROI	-61.40%	52W High	-95.34%	Beta	-1.15
Dividend %	-	Quick Ratio	11.76	Sales past 5Y	0.00%	Gross Margin	-	52W Low	3.23%	ATR	0.72
Employees	59	Current Ratio	11.76	Sales Q/Q	-	Oper. Margin	0.00%	RSI (14)	12.28	Volatility	6.04% 8.58%
Optionable	Yes	Debt/Eq	0.04	EPS Q/Q	-55.63%	Profit Margin	-	Rel Volume	2.38	Prev Close	2.16
Shortable	Yes	LT Debt/Eq	0.04	Earnings	Nov 09 AMC	Payout	-	Avg Volume	2.13M	Price	2.20
Recom	2.40	SMA20	-48.28%	SMA50	-86.18%	SMA200	-92.85%	Volume	5,071,110	Change	1.85%

Date	Action	Analyst	Rating Change	Price Target Change
Nov-07-23	Downgrade	Wells Fargo	Overweight → Equal Weight	$77 → $8
Nov-07-23	Downgrade	Stifel	Buy → Hold	$6
Nov-07-23	Downgrade	Oppenheimer	Outperform → Perform
Nov-07-23	Downgrade	Morgan Stanley	Overweight → Equal-Weight	$46 → $6
Nov-07-23	Downgrade	H.C. Wainwright	Buy → Neutral
Jun-14-23	Resumed	Credit Suisse	Outperform	$63
Mar-21-23	Initiated	Wells Fargo	Overweight	$77
Dec-19-22	Initiated	Goldman	Buy	$50
Nov-17-22	Initiated	Morgan Stanley	Overweight	$45
Sep-07-22	Initiated	Stifel	Buy	$45
Sep-01-22	Initiated	H.C. Wainwright	Buy	$36
May-09-22	Initiated	Credit Suisse	Outperform	$53
Mar-31-22	Initiated	Canaccord Genuity	Buy	$30
Feb-01-22	Initiated	Oppenheimer	Outperform	$30
Nov-15-21	Initiated	Piper Sandler	Overweight	$50
Nov-15-21	Initiated	Jefferies	Buy	$30

Show Previous Ratings

Nov-21-23 04:05PM	Ventyx Biosciences to Participate in the 35th Annual Piper Sandler Healthcare Conference (GlobeNewswire)
Nov-10-23 08:00AM	Ventyx Biosciences to Participate in the Jefferies London Healthcare Conference (GlobeNewswire) -7.17%
Nov-09-23 04:01PM	Ventyx Biosciences Reports Third Quarter 2023 Financial Results and Highlights Recent Corporate Progress (GlobeNewswire) -5.15%
09:35AM	Down -86.57% in 4 Weeks, Here's Why Ventyx Biosciences, Inc. (VTYX) Looks Ripe for a Turnaround (Zacks)
Nov-07-23 04:20PM	Ventyx Crashes 81% After Scrapping Two Studies On A Psoriasis Treatment Flop (Investor's Business Daily) -80.62%
08:47AM	Loading…
08:47AM	Why Is Ventyx Biosciences (VTYX) Stock Down 76% Today? (InvestorPlace)
07:00AM	Ventyx revises TYK2 drug plans after lackluster study data (BioPharma Dive)
Nov-06-23 04:01PM	Ventyx Biosciences Announces Results from the Phase 2 Trial of VTX958 in Patients with Moderate to Severe Plaque Psoriasis and Provides Corporate Update (GlobeNewswire) -9.56%
Nov-04-23 12:16PM	12 Best Small-Cap Biotech Stocks with Massive Potential According to Hedge Funds (Insider Monkey)
Oct-11-23 11:37AM	Ventyx (VTYX) Down Despite Positive Ulcerative Colitis Study Data (Zacks) -8.87%
Oct-10-23 04:18PM	These Stocks Are Moving the Most Today: PepsiCo, Truist, Unity Software, Rivian, Electronic Arts, and More (Barrons.com) -25.93%
12:55PM	Why Shares of Ventyx Biosciences Are Dropping Tuesday (Motley Fool)
07:44AM	Health Care Roundup: Market Talk (The Wall Street Journal)
Oct-09-23 04:01PM	Ventyx Biosciences Announces Positive Results from the Phase 2 Trial of VTX002 in Patients with Moderate-to-Severely Active Ulcerative Colitis (GlobeNewswire)
Oct-07-23 05:00AM	CEO Raju Mohan Sells 30,000 Shares of Ventyx Biosciences Inc (VTYX) (GuruFocus.com)
11:01PM	Loading…
Oct-04-23 11:01PM	Insider Sell: Christopher Krueger Sells 15,000 Shares of Ventyx Biosciences Inc (VTYX) (GuruFocus.com) -5.98%
Sep-29-23 12:43PM	25 Biggest Stocks with Negative Beta (Insider Monkey)
Sep-08-23 05:07PM	Insider Sell: CFO Martin Auster Sells 26,472 Shares of Ventyx Biosciences Inc (GuruFocus.com)
Aug-30-23 04:05PM	Ventyx Biosciences to Participate in Two Upcoming Investor Conferences (GlobeNewswire)
Aug-15-23 07:23AM	Ventyx Biosciences, Inc. (NASDAQ:VTYX) Q2 2023 Earnings Call Transcript (Insider Monkey)
Aug-10-23 04:01PM	Ventyx Biosciences Reports Second Quarter 2023 Financial Results and Highlights Recent Corporate Progress (GlobeNewswire) +6.38%
Aug-03-23 04:05PM	Ventyx Biosciences to Report Second Quarter 2023 Financial Results on August 10, 2023 (GlobeNewswire)
Aug-02-23 04:06PM	Ventyx Biosciences to Participate in the Canaccord Genuity 43rd Annual Growth Conference (GlobeNewswire)
Jul-12-23 07:22AM	Daily Vickers Top Buyers & Sellers for 07/12/2023 (Argus Research) -5.95%
Jul-03-23 02:09PM	Why Shares of Ventyx Biosciences Rose Monday (Motley Fool) +22.87%
Jun-14-23 07:00AM	Ventyx Biosciences Announces Initiation of Dosing in a Phase 1 Trial of VTX3232, a Novel CNS-Penetrant NLRP3 Inhibitor (GlobeNewswire)
Jun-07-23 07:00AM	Ventyx Biosciences Announces Completion of Enrollment of the Phase 2 Trial of VTX002 in Ulcerative Colitis and the Phase 2 Trial of VTX958 in Plaque Psoriasis (GlobeNewswire)
May-31-23 08:00AM	Ventyx Biosciences to Participate in Two Upcoming Investor Conferences (GlobeNewswire)
May-12-23 08:57AM	Q1 2023 Ventyx Biosciences Inc Earnings Call (Thomson Reuters StreetEvents) -7.11%
May-11-23 04:01PM	Ventyx Biosciences Reports First Quarter 2023 Financial Results and Highlights Recent Corporate Progress (GlobeNewswire)
04:05PM	Loading…
May-04-23 04:05PM	Ventyx Biosciences to Report First Quarter 2023 Financial Results on May 11, 2023 (GlobeNewswire)
Mar-27-23 07:12AM	Ventyx Biosciences, Inc. (NASDAQ:VTYX) Q4 2022 Earnings Call Transcript (Insider Monkey)
Mar-24-23 11:13AM	Q4 2022 Ventyx Biosciences Inc Earnings Call (Thomson Reuters StreetEvents) -5.23%
08:00AM	Ventyx Biosciences to Participate in the H.C. Wainwright Autoimmune & Inflammatory Disease Virtual Conference (GlobeNewswire)
Mar-23-23 04:01PM	Ventyx Biosciences Reports Fourth Quarter and Full Year 2022 Financial Results and Highlights Recent Corporate Progress (GlobeNewswire)
Mar-15-23 04:05PM	Ventyx Biosciences to Report Fourth Quarter and Full Year 2022 Financial Results on March 23, 2023 (GlobeNewswire)
Mar-13-23 09:02AM	Companies Like Ventyx Biosciences (NASDAQ:VTYX) Are In A Position To Invest In Growth (Simply Wall St.)
Mar-11-23 01:21PM	Ventyx Biosciences Provides Update on Silicon Valley Bank Financial Exposure (GlobeNewswire)
Feb-28-23 08:00AM	Ventyx Biosciences to Participate in Three Upcoming Investor Conferences (GlobeNewswire)
Feb-27-23 08:50AM	Recent Price Trend in Ventyx Biosciences, Inc. (VTYX) is Your Friend, Here's Why (Zacks)
Feb-13-23 09:55AM	Wall Street Analysts See a 26.67% Upside in Ventyx Biosciences, Inc. (VTYX): Can the Stock Really Move This High? (Zacks)
Feb-10-23 08:50AM	Ventyx Biosciences, Inc. (VTYX) Is a Great Choice for 'Trend' Investors, Here's Why (Zacks)
Feb-03-23 12:00PM	Are You Looking for a Top Momentum Pick? Why Ventyx Biosciences, Inc. (VTYX) is a Great Choice (Zacks)
Jan-26-23 09:55AM	Wall Street Analysts Think Ventyx Biosciences, Inc. (VTYX) Could Surge 38.99%: Read This Before Placing a Bet (Zacks)
08:00AM	Ventyx Biosciences Announces Pipeline Updates and Highlights Strategic Priorities at Investor R&D Day (GlobeNewswire)
Jan-25-23 08:50AM	Here's Why Momentum in Ventyx Biosciences, Inc. (VTYX) Should Keep going (Zacks)
Jan-12-23 08:00AM	Ventyx Biosciences Appoints Allison J. Hulme, Ph.D. and Onaiza Cadoret-Manier to its Board of Directors (GlobeNewswire)
Jan-05-23 08:00AM	Ventyx Biosciences to Host R&D Event on January 26, 2023 (GlobeNewswire)
Jan-04-23 09:55AM	Wall Street Analysts Predict a 71% Upside in Ventyx Biosciences, Inc. (VTYX): Here's What You Should Know (Zacks) +6.25%
Dec-27-22 07:11AM	Daily Vickers Top Buyers & Sellers for 12/27/2022 (Argus Research)
Dec-22-22 07:26AM	Ventyx Biosciences, Inc. (NASDAQ:VTYX) is a favorite amongst institutional investors who own 51% (Simply Wall St.)
Dec-01-22 04:05PM	Ventyx Biosciences Announces Dosing of the First Patient in the Phase 2 SERENITY Trial of VTX958 for the Treatment of Moderate to Severe Plaque Psoriasis (GlobeNewswire)
Nov-22-22 08:00AM	Ventyx Biosciences to Participate in Two Upcoming Investor Conferences (GlobeNewswire)
Nov-11-22 06:35PM	Rain Therapeutics and New York Times Stock See Action From Activist Investors (Barrons.com)
Nov-03-22 04:01PM	Ventyx Biosciences Reports Third Quarter 2022 Financial Results and Highlights Recent Corporate Progress (GlobeNewswire)
Oct-27-22 04:05PM	Ventyx Biosciences to Report Third Quarter 2022 Financial Results on November 3, 2022 (GlobeNewswire)
09:00AM	Ventyx Biosciences to Participate in Three Upcoming Investor Conferences (GlobeNewswire)
Oct-24-22 09:55AM	Ventyx Biosciences, Inc. (VTYX) May Find a Bottom Soon, Here's Why You Should Buy the Stock Now (Zacks)
Sep-19-22 09:31AM	10 Best-Performing Non-Energy Stocks of 2022 (Insider Monkey)
08:00AM	Ventyx Biosciences Announces $176.6 Million Private Placement of Common Stock (GlobeNewswire)
Sep-16-22 07:16PM	Why Ventyx Biosciences Zoomed Nearly 60% Higher This Week (Motley Fool)
Sep-14-22 02:01PM	Bristol Myers Squibb Shakes Up Key Biotech Battleground (TheStreet.com) +9.01%
Aug-29-22 04:05PM	Ventyx Biosciences to Participate in Two Upcoming Investor Conferences (GlobeNewswire)
Aug-16-22 03:52PM	This Inflammatory Disease Focused Stock Is Well Positioned For $12B Crohn's Disease Market (Benzinga) +31.99%
Aug-15-22 04:05PM	Ventyx Biosciences Reports Second Quarter 2022 Financial Results and Highlights Recent Corporate Progress (GlobeNewswire)
04:01PM	Ventyx Biosciences Announces Positive Topline Phase 1 Data for Its Selective Allosteric TYK2 Inhibitor VTX958 (GlobeNewswire)
Aug-11-22 04:05PM	Ventyx Biosciences to Report Topline Results from the Phase 1 trial of its TYK 2 Inhibitor VTX958 and Second Quarter 2022 Financial Results on August 15, 2022 (GlobeNewswire)
Jun-30-22 08:43AM	We Think Ventyx Biosciences (NASDAQ:VTYX) Can Afford To Drive Business Growth (Simply Wall St.)
Jun-29-22 08:00AM	Ventyx Biosciences Announces Positive Topline Phase 1 Data for its Peripheral NLRP3 Inhibitor VTX2735 (GlobeNewswire)
Jun-01-22 08:00AM	Ventyx Biosciences to Participate in the Jefferies Healthcare Conference (GlobeNewswire)
May-12-22 04:01PM	Ventyx Biosciences Reports First Quarter 2022 Financial Results and Highlights Recent Corporate Progress (GlobeNewswire) +7.79%
May-09-22 08:00AM	Ventyx Biosciences Announces Appointment of William Sandborn, MD, as President and Chief Medical Officer (GlobeNewswire) -9.12%
May-05-22 04:05PM	Ventyx Biosciences to Report First Quarter 2022 Financial Results on May 12, 2022 (GlobeNewswire)
Apr-20-22 10:16AM	Thomas Steyers Farallon Capital is Buying These 10 Stocks (Insider Monkey) +5.41%
09:43AM	10 Little-Known Stocks Billionaire Dan Loeb is Buying (Insider Monkey)
Mar-23-22 08:00AM	Ventyx Biosciences Reports Full Year 2021 Financial Results and Highlights Recent Corporate Progress (GlobeNewswire) +8.73%
Mar-07-22 08:00AM	Ventyx Biosciences to Participate in the Barclays Global Healthcare Conference (GlobeNewswire)
Mar-03-22 01:10PM	Oppenheimer Says These 2 Strong Buy Stocks Could Double This Year (TipRanks)
Jan-21-22 10:01AM	We're Not Very Worried About Ventyx Biosciences' (NASDAQ:VTYX) Cash Burn Rate (Simply Wall St.)
Dec-06-21 08:00AM	Ventyx Biosciences Announces First Patient Dosed in a Phase 2 Clinical Trial of VTX002 for the Treatment of Moderate-to-Severe Ulcerative Colitis (GlobeNewswire) -14.11%
Nov-19-21 08:00AM	Ventyx Biosciences to Participate in Two Upcoming Investor Conferences (GlobeNewswire)
Nov-17-21 04:11PM	Ventyx Biosciences Reports Third Quarter Financial Results and Provides Business Update (GlobeNewswire)
Nov-12-21 03:20PM	Lumen Technologies and Ventyx Biosciences Stock See Action From Activist Investors (Barrons.com)
Oct-25-21 04:58PM	Ventyx Biosciences Announces Closing of Upsized Initial Public Offering and Full Exercise of Underwriters Option to Purchase Additional Shares (GlobeNewswire)
Oct-20-21 08:38PM	Ventyx Biosciences Announces Pricing of Upsized Initial Public Offering (GlobeNewswire)

Ventyx Biosciences, Inc. is a clinical-stage biopharmaceutical company, which focuses on developing novel small molecule therapeutics for the treatment of autoimmune diseases. Its clinical stage pipeline includes VTX958, a Phase 1 allosteric TYK2 inhibitor for the treatment of a broad range of autoimmune diseases, VTX002, a Phase 2-ready S1P1 receptor modulator for the treatment of ulcerative colitis, and VTX2735, a Phase 1-ready peripheral inhibitor of the NLRP3 inflammasome, which is a mediator of multiple inflammatory conditions. The company was founded on November 21, 2018 and is headquartered in San Diego, CA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
NSV Partners III LP	10% Owner	Oct 09	Sale	30.03	49,152	1,475,858	8,439,635	Oct 11 04:21 PM
Subramaniam Somu	Director	Oct 09	Sale	30.03	49,152	1,475,858	8,439,635	Oct 11 04:18 PM
Mohan Raju	Chief Executive Officer	Oct 05	Option Exercise	8.04	30,000	241,200	1,542,911	Oct 06 07:16 PM
Mohan Raju	Chief Executive Officer	Oct 05	Sale	29.11	30,000	873,231	1,512,911	Oct 06 07:16 PM
Krueger Christopher W	Chief Business Officer	Oct 03	Option Exercise	8.04	15,000	120,600	291,548	Oct 04 07:33 PM
Nuss John	Chief Scientific Officer	Oct 03	Option Exercise	3.35	10,000	33,542	254,815	Oct 04 07:26 PM
Krueger Christopher W	Chief Business Officer	Oct 03	Sale	29.98	15,000	449,699	276,548	Oct 04 07:33 PM
Nuss John	Chief Scientific Officer	Oct 03	Sale	29.99	10,000	299,933	244,815	Oct 04 07:26 PM
NSV Partners III LP	10% Owner	Sep 18	Sale	37.81	56,665	2,142,634	8,488,787	Sep 20 07:16 PM
Subramaniam Somu	Director	Sep 18	Sale	37.81	56,665	2,142,634	8,488,787	Sep 20 07:19 PM
Mohan Raju	Chief Executive Officer	Sep 05	Option Exercise	8.04	30,000	241,200	1,542,911	Sep 07 04:25 PM
Krueger Christopher W	Chief Business Officer	Sep 05	Option Exercise	8.04	15,000	120,600	291,548	Sep 07 04:28 PM
Nuss John	Chief Scientific Officer	Sep 05	Option Exercise	0.20	10,000	2,000	254,815	Sep 07 04:21 PM
Mohan Raju	Chief Executive Officer	Sep 05	Sale	32.61	30,000	978,343	1,512,911	Sep 07 04:25 PM
Auster Martin	Chief Financial Officer	Sep 05	Sale	32.61	26,472	863,334	21,177	Sep 07 04:31 PM
Krueger Christopher W	Chief Business Officer	Sep 05	Sale	32.61	15,000	489,109	276,548	Sep 07 04:28 PM
Nuss John	Chief Scientific Officer	Sep 05	Sale	32.60	10,000	325,960	244,815	Sep 07 04:21 PM
Sandborn William J.	See Remarks	Aug 31	Option Exercise	14.85	11,900	176,715	60,289	Sep 01 04:45 PM
Sandborn William J.	See Remarks	Aug 31	Sale	33.64	11,900	400,354	48,389	Sep 01 04:45 PM
Sandborn William J.	See Remarks	Aug 08	Sale	32.86	3,494	114,810	24,194	Aug 08 06:57 PM
Mohan Raju	Chief Executive Officer	Aug 07	Option Exercise	8.04	30,000	241,200	1,542,911	Aug 08 06:54 PM
Mohan Raju	Chief Executive Officer	Aug 07	Sale	33.52	30,000	1,005,570	1,512,911	Aug 08 06:54 PM
Krueger Christopher W	Chief Business Officer	Aug 03	Option Exercise	8.04	15,000	120,600	291,548	Aug 04 06:06 PM
Nuss John	Chief Scientific Officer	Aug 03	Option Exercise	0.20	10,000	2,000	254,815	Aug 04 06:08 PM
Krueger Christopher W	Chief Business Officer	Aug 03	Sale	35.59	15,000	533,797	276,548	Aug 04 06:06 PM
Nuss John	Chief Scientific Officer	Aug 03	Sale	35.60	10,000	355,986	244,815	Aug 04 06:08 PM
Sandborn William J.	See Remarks	Jul 31	Option Exercise	14.85	11,900	176,715	60,289	Aug 01 04:21 PM
Sandborn William J.	See Remarks	Jul 31	Sale	37.16	11,900	442,261	48,389	Aug 01 04:21 PM
Subramaniam Somu	Director	Jul 31	Sale	37.59	10,803	406,035	8,545,452	Aug 01 05:44 PM
NSV Partners III LP	10% Owner	Jul 31	Sale	37.59	10,803	406,035	8,545,452	Aug 01 05:43 PM
NSV Partners III LP	10% Owner	Jul 28	Sale	37.53	611	22,933	8,556,255	Aug 01 05:43 PM
Subramaniam Somu	Director	Jul 28	Sale	37.53	611	22,933	8,556,255	Aug 01 05:44 PM
Auster Martin	Chief Financial Officer	Jul 25	Option Exercise	3.45	28,000	96,600	75,649	Jul 26 06:51 PM
Auster Martin	Chief Financial Officer	Jul 25	Sale	35.54	28,000	995,044	47,649	Jul 26 06:51 PM
Subramaniam Somu	Director	Jul 12	Sale	37.62	3,275	123,219	8,556,866	Jul 13 09:25 PM
NSV Partners III LP	10% Owner	Jul 12	Sale	37.62	3,275	123,219	8,556,866	Jul 13 09:26 PM
Subramaniam Somu	Director	Jul 11	Sale	37.54	28,646	1,075,411	8,560,141	Jul 13 09:25 PM
NSV Partners III LP	10% Owner	Jul 11	Sale	37.54	28,646	1,075,411	8,560,141	Jul 13 09:26 PM
Subramaniam Somu	Director	Jul 07	Sale	35.23	100,000	3,523,057	9,552,965	Jul 11 09:15 PM
NSV Partners III LP	10% Owner	Jul 07	Sale	35.23	100,000	3,523,057	9,552,965	Jul 11 09:13 PM
Mohan Raju	Chief Executive Officer	Jul 05	Option Exercise	8.04	29,785	239,471	1,542,911	Jul 05 08:23 PM
Mohan Raju	Chief Executive Officer	Jul 05	Sale	38.37	30,000	1,151,227	1,512,911	Jul 05 08:23 PM
Sandborn William J.	See Remarks	Jul 03	Option Exercise	14.85	11,900	176,715	60,289	Jul 05 08:16 PM
Krueger Christopher W	Chief Business Officer	Jul 03	Option Exercise	0.77	15,000	11,538	291,548	Jul 05 08:18 PM
Nuss John	Chief Scientific Officer	Jul 03	Option Exercise	0.20	20,000	4,000	264,815	Jul 05 08:20 PM
NSV Partners III LP	10% Owner	Jul 03	Sale	39.00	134,080	5,229,698	9,652,965	Jul 06 06:25 PM
Subramaniam Somu	Director	Jul 03	Sale	39.00	134,080	5,229,698	9,652,965	Jul 06 06:21 PM
Nuss John	Chief Scientific Officer	Jul 03	Sale	39.58	20,000	791,637	244,815	Jul 05 08:20 PM
Krueger Christopher W	Chief Business Officer	Jul 03	Sale	39.22	15,000	588,343	276,548	Jul 05 08:18 PM
Sandborn William J.	See Remarks	Jul 03	Sale	40.00	11,900	476,014	48,389	Jul 05 08:16 PM
Sandborn William J.	See Remarks	Jul 03	Sale	40.00	3,487	139,480	27,688	Jul 05 08:16 PM
Sandborn William J.	See Remarks	Jun 23	Option Exercise	0.20	10,790	2,158	59,179	Jun 27 06:01 PM
Sandborn William J.	See Remarks	Jun 23	Sale	32.70	10,790	352,844	48,389	Jun 27 06:01 PM
Sandborn William J.	See Remarks	Jun 15	Sale	34.15	3,487	119,092	31,175	Jun 16 09:16 PM
Subramaniam Somu	Director	Jun 14	Sale	35.08	50,000	1,753,785	9,787,045	Jun 16 07:21 PM
NSV Partners III LP	10% Owner	Jun 14	Sale	35.08	50,000	1,753,785	9,787,045	Jun 16 07:15 PM
NSV Partners III LP	10% Owner	Jun 07	Sale	35.66	35,872	1,279,108	9,837,045	Jun 08 09:47 PM
Subramaniam Somu	Director	Jun 07	Sale	35.66	35,872	1,279,108	9,837,045	Jun 08 09:50 PM
Auster Martin	Chief Financial Officer	Jun 06	Option Exercise	3.45	28,000	96,600	75,649	Jun 07 06:54 PM
Auster Martin	Chief Financial Officer	Jun 06	Sale	34.64	28,000	969,963	47,649	Jun 07 06:54 PM
Subramaniam Somu	Director	Jun 06	Sale	35.00	4,128	144,481	9,872,917	Jun 08 09:50 PM
NSV Partners III LP	10% Owner	Jun 06	Sale	35.00	4,128	144,481	9,872,917	Jun 08 09:47 PM
Krueger Christopher W	Chief Business Officer	Jun 05	Option Exercise	2.66	15,000	39,973	291,548	Jun 06 07:19 PM
Nuss John	Chief Scientific Officer	Jun 05	Option Exercise	0.20	10,000	2,000	254,815	Jun 07 06:59 PM
Mohan Raju	Chief Executive Officer	Jun 05	Sale	34.36	30,000	1,030,652	1,513,126	Jun 06 07:18 PM
Krueger Christopher W	Chief Business Officer	Jun 05	Sale	34.36	15,000	515,379	276,548	Jun 06 07:19 PM
Nuss John	Chief Scientific Officer	Jun 05	Sale	34.35	10,000	343,467	244,815	Jun 07 06:59 PM
Sandborn William J.	See Remarks	May 31	Option Exercise	0.20	10,629	2,126	59,018	Jun 01 05:53 PM
Sandborn William J.	See Remarks	May 31	Sale	34.26	10,629	364,155	48,389	Jun 01 05:53 PM
Sandborn William J.	See Remarks	May 15	Option Exercise	0.20	3,272	654	38,149	May 16 07:10 PM
Sandborn William J.	See Remarks	May 15	Sale	36.47	3,487	127,182	34,662	May 16 07:10 PM
Mohan Raju	Chief Executive Officer	May 05	Sale	39.28	30,000	1,178,502	1,543,126	May 05 08:54 PM
Krueger Christopher W	Chief Business Officer	May 03	Option Exercise	8.04	15,000	120,600	291,117	May 04 04:07 PM
Nuss John	Chief Scientific Officer	May 03	Option Exercise	0.20	10,000	2,000	254,815	May 04 04:10 PM
Krueger Christopher W	Chief Business Officer	May 03	Sale	38.65	15,000	579,699	276,117	May 04 04:07 PM
Nuss John	Chief Scientific Officer	May 03	Sale	38.64	10,000	386,371	244,815	May 04 04:10 PM
Sandborn William J.	See Remarks	Apr 28	Option Exercise	0.20	10,790	2,158	59,179	May 01 05:36 PM
Sandborn William J.	See Remarks	Apr 28	Sale	36.96	10,790	398,755	48,389	May 01 05:36 PM
Auster Martin	Chief Financial Officer	Apr 25	Option Exercise	3.45	28,000	96,600	75,649	Apr 27 04:55 PM
Auster Martin	Chief Financial Officer	Apr 25	Sale	38.04	28,000	1,064,990	47,649	Apr 27 04:55 PM
Subramaniam Somu	Director	Apr 25	Sale	38.88	793	30,832	9,877,045	Apr 25 09:38 PM
NSV Partners III LP	10% Owner	Apr 25	Sale	38.88	793	30,832	9,877,045	Apr 25 09:39 PM
NSV Partners III LP	10% Owner	Apr 24	Sale	38.64	90,565	3,498,983	9,877,838	Apr 25 09:39 PM
Subramaniam Somu	Director	Apr 24	Sale	38.64	90,565	3,498,983	9,877,838	Apr 25 09:38 PM
Subramaniam Somu	Director	Apr 21	Sale	37.51	8,642	324,178	9,968,403	Apr 25 09:38 PM
NSV Partners III LP	10% Owner	Apr 21	Sale	37.51	8,642	324,178	9,968,403	Apr 25 09:39 PM
Auster Martin	Chief Financial Officer	Apr 17	Option Exercise	3.45	7,000	24,150	54,649	Apr 19 04:51 PM
Auster Martin	Chief Financial Officer	Apr 17	Sale	33.00	7,000	231,013	47,649	Apr 19 04:51 PM
NSV Partners III LP	10% Owner	Apr 13	Sale	30.31	71,446	2,165,800	9,977,045	Apr 14 06:33 PM
Subramaniam Somu	Director	Apr 13	Sale	30.31	71,446	2,165,800	9,977,045	Apr 14 06:35 PM
NSV Partners III LP	10% Owner	Apr 12	Sale	30.01	28,554	856,866	10,048,491	Apr 14 06:33 PM
Subramaniam Somu	Director	Apr 12	Sale	30.01	28,554	856,866	10,048,491	Apr 14 06:35 PM
Mohan Raju	Chief Executive Officer	Apr 10	Sale	29.01	9,255	268,519	1,573,126	Apr 12 04:58 PM
Mohan Raju	Chief Executive Officer	Apr 06	Sale	29.01	7,515	217,991	1,582,381	Apr 07 03:47 PM
Mohan Raju	Chief Executive Officer	Apr 05	Sale	29.81	13,230	394,411	1,589,896	Apr 07 03:47 PM
Auster Martin	Chief Financial Officer	Apr 04	Option Exercise	3.45	21,000	72,450	68,649	Apr 05 07:18 PM
Auster Martin	Chief Financial Officer	Apr 04	Sale	30.76	21,000	646,035	47,649	Apr 05 07:18 PM
Nuss John	Chief Scientific Officer	Apr 03	Option Exercise	0.20	30,000	6,000	274,815	Apr 05 07:13 PM
Nuss John	Chief Scientific Officer	Apr 03	Sale	32.87	30,000	986,233	244,815	Apr 05 07:13 PM
Gujrathi Sheila	Director	Mar 30	Option Exercise	6.03	100,000	603,000	100,000	Mar 31 04:46 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

VTYX

Ventyx Biosciences Inc

Upgrade your FINVIZ experience